

Ministry of Health

# COVID-19 Vaccine Third Dose Recommendations

Version 7.1 February 17, 2022

## Highlights of changes

- Recommended interval to receive a booster dose post COVID-19 infection ([page 4](#))
- Booster dose eligibility for individuals 12-17 years of age ([page 12](#))

This guidance provides basic information only. This document is not intended to provide or take the place of medical advice, diagnosis or treatment, or legal advice.

- Please check the Ministry of Health (MOH) [COVID-19](#) website regularly for updates to this document, mental health resources, and other information.

## Table of Contents

Background.....	4
Third Dose: 3-Dose Primary Series vs. Booster Dose.....	5
3-Dose Primary Series for Moderately to Severely Immunocompromised.....	5
Booster Doses for Specific Populations .....	12
Fourth Doses for Specific Populations .....	13
Booster/4 <sup>th</sup> Dose Observation Period:.....	14
Table 2: Rationale and Options for Vaccine Type and Dose offered for COVID-19 Vaccine Booster Doses in Certain Populations.....	16
Booster dose prioritized populations: .....	18
1. Residents of Long-Term Care Homes (LTCH), Retirement Homes (RH), Elder Care Lodges, and older adults living in other congregate settings.....	18
2. Adults ≥50 years of age. ....	19
3. Health Care Workers.....	19
4. First Nations, Inuit and Métis Adults.....	20
5. Recipients of a Viral Vector Vaccine Primary Series that was completed with only viral vector vaccines (AstraZeneca/COVISHIELD or Janssen COVID-19 vaccine).....	21
Appendix A: List of Immunosuppressive Medications in Alphabetical Order.....	23
Appendix B: List of Health Care Workers Eligible for Booster Doses.....	24

## Background

The Ministry of Health is closely monitoring the prevalence of the Delta and Omicron variants of concern globally and within Ontario, specifically with respect to the level of transmissibility and disease severity.

**Achieving high first and second dose coverage remains the focus and main priority of the Ontario's COVID-19 vaccination program. In response to the changing risk posed by the Omicron variant, accelerated deployment of COVID-19 boosters may provide increased protection across the population.** To date, a primary series of the COVID-19 vaccines have been shown to maintain high vaccine effectiveness with no evidence of waning against serious illness, hospitalization, and death from COVID-19 in most populations. Despite some evidence of increasing risk of breakthrough infection over time, those vaccinated against COVID-19 with a two-dose series continue to demonstrate significantly lower odds of SARS-CoV-2 infection compared to unvaccinated individuals and, when infections occur, symptoms tend to be milder in vaccinated cases ([NACI, 2021](#)). However, evidence is emerging that vaccine effectiveness against infection and COVID-19 disease decreases with time, and the effectiveness of currently authorized COVID-19 vaccines against the Omicron variant is uncertain. Therefore, for certain populations, an additional dose may be needed to obtain more durable protection.

The Pfizer-BioNTech and Moderna COVID-19 vaccines have been [authorized for use](#) by Health Canada as a booster dose after completion of the primary series in individuals 18 years of age and older. A risk/benefit analysis for individual patients is at the center of the collaborative clinician/patient decision-making process. Informed consent for additional doses of COVID-19 vaccine should clearly communicate what is known and unknown about the risks and benefits of an additional dose. Evidence from clinical trials suggests that booster doses of mRNA vaccines given six months after the primary series elicited a robust immune response. Real world data suggests that a booster dose provides good short-term vaccine effectiveness and has a safety profile similar to the second dose of the vaccine. There is no evidence on the long-term effectiveness of booster doses so it remains unknown at this time how long this protective benefit might last. The evidence on the risk of myocarditis/pericarditis after a booster dose of an mRNA vaccine is limited, but appears to be lower than the already rare risk after the second dose of the primary series but higher than after the first dose ([NACI, 2021](#)). See [NACI guidance](#) for more information on the evidence, safety and immunogenicity of COVID-19 booster doses. In most circumstances, and as a precautionary measure until more information is available, further doses of mRNA

COVID-19 vaccines should be deferred among people who experienced myocarditis (with or without pericarditis) within 6 weeks of receiving a previous dose of an mRNA COVID-19 vaccine. This includes any person who had an abnormal cardiac investigation including electrocardiogram (ECG), elevated troponins, echocardiogram or cardiac MRI after a dose of an mRNA vaccine. Those with a history compatible with pericarditis and who either had no cardiac workup or had normal cardiac investigations, can receive the next dose once they are symptom free and at least 90 days has passed since vaccination ([NACI, 2022](#)). For more detailed information regarding (re)immunization following myocarditis/pericarditis, see the [Medical Exemption Guidance](#).

Individuals that received AstraZeneca/COVISHIELD COVID-19 vaccine for their first and second dose are recommended to receive an mRNA vaccine for their third or booster dose. People who experienced a severe immediate allergic reaction after a first dose of an mRNA COVID-19 vaccine can safely receive future doses of the same or another mRNA COVID-19 vaccine after consulting with an allergist/immunologist or another appropriate physician. See [the Canadian Immunization Guide for NACI's recommendations on the use of COVID-19 vaccines](#) for more information. If an individual needs to receive a booster dose of a viral vector vaccine, [informed consent](#) should include discussion about the increased risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), Capillary Leak Syndrome (CLS), and Guillain-Barre syndrome (GBS) following viral vector COVID-19 vaccines and the very limited evidence on the use and effectiveness of an additional dose of viral vector COVID-19 vaccine. ([NACI, 2021](#)).

Individuals 12 years of age and older, infected\* with COVID-19 after their primary series but before their booster dose, are recommended to receive their booster dose 3 months after symptom onset or positive test (if asymptomatic) and, for 12 to 17 years olds, provided it is at least 6 months from completing the primary series. As per [NACI](#), emerging evidence indicates that a longer interval between SARS-CoV-2 infection and vaccination is associated with improved antibody responses to COVID-19 vaccines. With informed consent, individuals may receive a booster dose once they are asymptomatic and have completed their isolation.

\*A previous infection with SARS-CoV-2 is defined as a COVID-19 case confirmed by a molecular (e.g., PCR) or rapid antigen test, or [symptomatic](#) AND a household contact of a confirmed COVID-19 case.

The Ministry of Health, Public Health Ontario (PHO) and NACI are closely following the research on the safety and effectiveness of additional doses. Recommendations will be re-examined on an ongoing basis as new data emerges. Recommendations will be issued as part of Ontario's ongoing COVID-19 vaccination program as further evidence becomes available. Serological testing is not recommended before or after COVID-19 vaccination ([NACI, 2021](#)).

For additional doses related to out of province vaccination, see the MOH [COVID-19 Guidance for Individuals Vaccinated outside of Ontario/Canada](#).

## Third Dose: 3-Dose Primary Series vs. Booster Dose

Historically in other vaccine programs, it takes years of post-marketing surveillance to determine the optimal interval between doses and dose number to complete a primary series to sustain long-term protection. Per NACI's [guidance on booster COVID-19 vaccine doses in Canada](#), the intent of a booster dose is to restore protection that may have decreased over time to a level that is no longer deemed sufficient in individuals who initially responded adequately to a complete primary vaccine series. This is distinguished from the intent of a third dose which might be added to the standard primary vaccine series with the aim of enhancing the immune response and establishing an adequate level of protection for individuals who developed no or a sub-optimal immune response to a 2-dose primary series. While the term "booster dose" is used in this guidance, NACI continues to monitor the emerging scientific data on whether this dose is indeed a booster dose (to stimulate the memory response once protection has truly waned), or should be considered part of the primary series (to establish strong immune response and memory). NACI will adjust the terminology as required. See [NACI interim guidance](#) for more information.

## 3-Dose Primary Series for Moderately to Severely Immunocompromised

### Rationale:

- Certain populations are at increased risk of severe outcomes from COVID-19, and have demonstrated a sub-optimal immune response to a complete two-dose COVID-19 vaccine series due to their underlying condition. See the COVID-19 chapter in the [Canadian Immunization Guide about NACI's Rapid Response Statement: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series](#) for more information.
- There is emerging evidence on the safety and immunogenicity following a third dose of a COVID-19 vaccine for those that have not seroconverted following their second dose in select immunocompromised populations. Certain moderately and severely immunocompromised populations may benefit from a third dose to complete a primary COVID-19 vaccines series.

**Recommendations:**

- At this time a third dose of the mRNA COVID-19 vaccine will be offered for the following populations eligible for vaccination with the vaccine product authorized for their age group (these recommendations also apply to children aged 5-11 who fall within any of the categories below), to complete the primary COVID-19 vaccine series:
  - Individuals receiving dialysis (hemodialysis or peritoneal dialysis)
  - Individuals receiving active treatment<sup>1</sup> (e.g., chemotherapy, targeted therapies, immunotherapy) for solid tumour or hematologic malignancies
  - Recipients of solid-organ transplant and taking immunosuppressive therapy
  - Recipients of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  - Individuals with moderate to severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  - Individuals with HIV with prior AIDS defining illness **or** prior CD4 count  $\leq$  200/mm<sup>3</sup> **or** prior CD4 fraction  $\leq$  15% **or** (in children 5-11 years) perinatally acquired HIV infection
  - Individuals receiving active treatment with the following categories of immunosuppressive therapies: anti-B cell therapies<sup>2</sup> (monoclonal antibodies targeting CD19, CD20 and CD22), high-dose systemic corticosteroids (refer to the [Canadian Immunization Guide](#) for suggested definition of high dose steroids), alkylating agents, antimetabolites, or tumor-necrosis factor (TNF) inhibitors and other biologic agents that are significantly immunosuppressive (See Table 1).
- For individuals with one of the above immune compromising conditions who have not initiated a COVID-19 vaccine series, individuals in the authorized age

---

<sup>1</sup> Active treatment includes patients who have completed treatment within 3 months. Active treatment is defined as chemotherapy, targeted therapies, immunotherapy, and excludes individuals receiving therapy that does not suppress the immune system (e.g., solely hormonal therapy or radiation therapy). See Ontario Health/Cancer Care Ontario's [Frequently Asked Questions](#) for more information.

<sup>2</sup> Active treatment for patients receiving B-cell depleting therapy includes patients who have completed treatment within 12 months.

group should be immunized with a primary series of three doses of an authorized mRNA vaccine. ([NACI, 2021](#)). Either Moderna or Pfizer vaccines may be used as a third dose (regardless of which COVID-19 vaccine was used in the primary series). Immunocompromised individuals should be offered the full dose of either Moderna (100 mcg) or Pfizer-BioNTech (30 mcg) as a third dose. Individuals between the ages of 12-29 are preferentially recommended to receive Pfizer-BioNTech but may receive Moderna (100mcg) with [informed consent](#). For children ages 5-11, the pediatric Pfizer-BioNTech (10mcg) vaccine should be given.

- The Ontario recommended interval between the second dose of the initial primary series and the third dose is at least two months (56 days). As per NACI, the minimum interval is 28 days; however, an interval longer than the minimum of 28 days between doses is likely to result in a better immune response. Exact timing should be decided with the treating provider in order to optimize the immune response from the vaccine series and minimize delays in management of the individual's underlying condition. Additionally, the interval should consider risk factors for exposure (including local epidemiology and circulation of variants of concern) and risk of severe disease from SARS-CoV-2 infection. Some immunocompromised individuals may still be susceptible after the 1 or 2-dose primary series, so their period of susceptibility until receipt of the additional dose will also increase if the interval between doses is increased.
- Moderately to severely immunocompromised individuals (18 years of age and older) who are eligible for a three-dose primary series are recommended to receive a booster dose (i.e. 4<sup>th</sup> dose)  $\geq 3$  months (84 days) after completion of the extended primary series. Moderately to severely immunocompromised individuals (12 to 17 year olds) who are eligible for a three-dose primary series are recommended to receive a booster dose (i.e. 4<sup>th</sup> dose)  $\geq 6$  months (168 days) after completion of the extended primary series or at an interval recommended by their provider. See section on booster doses for more information.

Booster doses (i.e. 4<sup>th</sup> dose) are not currently recommended for moderately to severely immunocompromised individuals under the age of 12.

- Individuals (12 years of age and older) who were receiving active treatment necessitating a three dose primary series, are eligible for a booster dose, even if not receiving active treatment currently.

- For guidance on the timing of vaccination for transplant recipients and those requiring immunosuppressive therapies, for a more fulsome list of conditions leading to primary immunodeficiency, and for further information on immunosuppressive therapies, refer to [Immunization of Immunocompromised Persons in the Canadian Immunization Guide \(CIG\), Part 3 – Vaccination of Specific Populations](#).
- To protect those who are immunocompromised, it also is strongly recommended that all people that come into close contact (e.g., healthcare workers and other support staff, family, friends, caregivers) with these individuals complete a full two-dose vaccine series (i.e., “ring vaccination”). Immunocompromised individuals and those that come into close contact with them should also continue to follow recommended public health measures for prevention and control of SARS-CoV-2 infection and transmission.

**Table 1: List of Significantly Immunosuppressive Medications**

\*This list may not be comprehensive; health care providers may identify patients on other medications that are significantly immunosuppressive. Prescriptions for the below immunosuppressant medications can be presented for additional doses as needed. If an individual presents a prescription of a medication that is not listed in Table 1, they should be directed to their health care provider to receive a referral form/letter for a third and any subsequent dose(s) of a COVID-19 vaccine.

Class	Generic Name(s)	Brand Name(s)
Steroids (>20 mg per day of prednisone or equivalent for at least 2 weeks) <sup>3</sup>	• Prednisone	
	• dexamethasone	• Decadron
	• methylprednisolone	• DepoMedrol • SoluMedrol • Medrol

<sup>3</sup> As the dosing information may not be included on the patient's prescription, confirmation of the dosage from the individual presenting their prescription is sufficient. Equivalent steroid dose (prednisone 20 mg = prednisolone 20 mg = methylprednisolone 16 mg = hydrocortisone 80 mg = dexamethasone 3 mg)

<b>Class</b>	<b>Generic Name(s)</b>	<b>Brand Name(s)</b>
Antimetabolites	• cyclophosphamide	• Procytox
	• leflunomide	• Arava
	• methotrexate	• Trexall • Metoject • Otrexup • Rasuvo • Rheumatrex
	• azathioprine	• Imuran
	• 6- mercaptopurine (6-MP)	• Purinethol
	• mycophenolic acid	• Myfortic
	• mycophenolate mofetil	• Cellcept
Calcineurin inhibitors/mTOR kinase inhibitor	• tacrolimus	• Prograf • Advagraf • Envarsus PA
	• cyclosporine	• Neoral • Gengraf • Sandimmune
	• sirolimus	• Rapamune
JAK (Janus kinase) inhibitors	• baricitinib	• Olumiant
	• tofacitinib	• Xeljanz
	• upadacitinib	• Rinvoq

<b>Class</b>	<b>Generic Name(s)</b>	<b>Brand Name(s)</b>
Anti-TNF (tumor necrosis factor)	<ul style="list-style-type: none"> <li>adalimumab</li> </ul>	<ul style="list-style-type: none"> <li>Humira</li> <li>Amgevita</li> <li>Hadlima</li> <li>Hulio</li> <li>Hyrimoz</li> <li>Idacio</li> </ul>
	<ul style="list-style-type: none"> <li>golimumab</li> </ul>	<ul style="list-style-type: none"> <li>Simponi</li> </ul>
	<ul style="list-style-type: none"> <li>certolizumab pegol</li> </ul>	<ul style="list-style-type: none"> <li>Cimzia</li> </ul>
	<ul style="list-style-type: none"> <li>etanercept</li> </ul>	<ul style="list-style-type: none"> <li>Enbrel</li> <li>Brenzys</li> <li>Erelzi</li> </ul>
	<ul style="list-style-type: none"> <li>infliximab</li> </ul>	<ul style="list-style-type: none"> <li>Remicade</li> <li>Avsola</li> <li>Inflectra</li> <li>Remsima</li> <li>Renflexis</li> </ul>
Anti-Inflammatory	<ul style="list-style-type: none"> <li>Sulfasalazine</li> </ul>	<ul style="list-style-type: none"> <li>Salazopyrin</li> <li>Azulfidine</li> </ul>
	<ul style="list-style-type: none"> <li>5-Aminosalicylic Acid (ASA)/mesalamine</li> </ul>	<ul style="list-style-type: none"> <li>Pentasa</li> </ul>

<b>Class</b>	<b>Generic Name(s)</b>	<b>Brand Name(s)</b>
Anti-CD20	<ul style="list-style-type: none"> <li>• Rituximab</li> </ul>	<ul style="list-style-type: none"> <li>• Rituxan</li> <li>• Ruxience</li> <li>• Riximyo</li> <li>• Truxima</li> <li>• Riabni</li> </ul>
	<ul style="list-style-type: none"> <li>• ocrelizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Ocrevus</li> </ul>
	<ul style="list-style-type: none"> <li>• ofatumumab</li> </ul>	<ul style="list-style-type: none"> <li>• Kesimpta</li> </ul>
IL-1 RA (interleukin-1 receptor antagonist)	<ul style="list-style-type: none"> <li>• anakinra</li> </ul>	<ul style="list-style-type: none"> <li>• Kineret</li> </ul>
	<ul style="list-style-type: none"> <li>• canakinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Ilaris</li> </ul>
Anti-IL6	<ul style="list-style-type: none"> <li>• tocilizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Actemra</li> </ul>
	<ul style="list-style-type: none"> <li>• sarilumab</li> </ul>	<ul style="list-style-type: none"> <li>• Kevzara</li> </ul>
Anti-IL12/IL23	<ul style="list-style-type: none"> <li>• ustekinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Stelara</li> </ul>
Anti-IL17	<ul style="list-style-type: none"> <li>• secukinumab</li> </ul>	<ul style="list-style-type: none"> <li>• Cosentyx</li> </ul>
	<ul style="list-style-type: none"> <li>• ixekizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Taltz</li> </ul>
Anti-IL17R	<ul style="list-style-type: none"> <li>• brodalumab</li> </ul>	<ul style="list-style-type: none"> <li>• Siliq</li> </ul>
Anti-BLyS	<ul style="list-style-type: none"> <li>• belimumab</li> </ul>	<ul style="list-style-type: none"> <li>• Benlysta</li> </ul>
Anti-IL23	<ul style="list-style-type: none"> <li>• guselkumab</li> </ul>	<ul style="list-style-type: none"> <li>• Tremfya</li> </ul>
	<ul style="list-style-type: none"> <li>• risankizumab</li> </ul>	<ul style="list-style-type: none"> <li>• Skyrizi</li> </ul>
Selective T-cell costimulation blocker	<ul style="list-style-type: none"> <li>• abatacept</li> </ul>	<ul style="list-style-type: none"> <li>• Orencia</li> </ul>

Class	Generic Name(s)	Brand Name(s)
S1PR (sphingosine 1-phosphate receptor) agonist	• fingolimod	• Gilenya
	• siponimod	• Mayzent
	• ozanimod	• Zeposia
Phosphodiesterase inhibitors	• Apremilast	• Otezla
Anti-integrin	• vedolizumab	• Entyvio

## Booster Doses for Specific Populations

On December 3<sup>rd</sup>, 2021, NACI released [updated recommendations](#) for booster doses, based upon emerging evidence on vaccine effectiveness, the risks of exposure to SARS-CoV-2 in Canada at this time, the revised objectives of Canada's COVID-19 immunization program, the ongoing risk of severe illness from COVID-19, the societal disruption that results from transmission of infections, and the adverse impacts on health system capacity of the COVID-19 pandemic. On February 17th, 2022, Ontario has expanded booster eligibility to individuals  $\geq 12$  years of age.

Ontario strongly recommends that a booster dose of an mRNA vaccine should be offered to individuals  $\geq 50$  years of age following  **$\geq 3$  months (84 days)** after completion of a primary COVID-19 vaccine series. This  $\geq 3$  month (84 days) recommended interval also now applies to all populations prioritized earlier in the booster dose roll out (as listed on page 12-17).

All individuals in Ontario aged  $\geq 18$  are eligible to receive booster doses of an mRNA vaccine  **$\geq 3$  months (84 days)** after completion of a primary COVID-19 vaccine series.

Individuals in Ontario aged 12-17 years of age are eligible to receive booster doses of an mRNA vaccine  **$\geq 6$  months (168 days)** after completion of a primary COVID-19 vaccine series. This interval may be associated with a lower risk of myocarditis with or without pericarditis. With informed consent, individuals 12-17 years of age may receive a booster dose at a minimum of 3 months (84 days) after completion of a primary COVID-19 vaccine series.

## Fourth Doses for Specific Populations

Residents of long-term care homes and retirement homes, and older adults living in other congregate settings are at increased risk for both COVID-19 infection and severe disease, such as hospitalization and death. Many of these individuals are now up to five months from their third dose and are likely becoming increasingly susceptible to COVID-19 infection due to waning immunity. A fourth dose of an mRNA vaccine is recommended for residents of long-term care homes (LTCH), retirement homes (RH), Elder Care Lodges and older adults living in other congregate settings providing assisted-living and health services\* who received their third dose at least **three months (84 days)** prior.

\*This includes assistance with: bathing, hygiene, ambulation, feeding, dressing, continence care, skin care, dementia care, provision of meals, administration of medications, nursing, or medical services. Other congregate settings may include chronic care hospitals, or older adults living in congregate settings for people with developmental disabilities, or older adults living in congregate settings focussed on mental health and addictions

## Booster/4<sup>th</sup> Dose Observation Period:

Given the urgency to provide booster doses, the **15-minute observation period for booster doses of mRNA vaccines could be waived on a temporary basis during the emergency response to the Omicron variant. A reduced post-vaccination observation period, between 5 -15 minutes could be considered for the administration of third booster doses of COVID-19 vaccine during the pandemic, if specific conditions are met** such as past experience with the two previous COVID-19 vaccine doses and other relevant [conditions](#) as outlined in the NACI 2020-2021 influenza vaccine advice. This would be an exception to usual immunization guidance and this approach could be used in these settings (i.e., mass immunization clinic, primary care clinics, pharmacies) at this time on a temporary basis during the emergency response to the Omicron variant, weighing the risks of a reduction in observation period (e.g., small increased risk of delayed identification of an adverse event that may require immediate medical attention) with reducing risk of SARS-CoV-2 transmission where physical distancing cannot be maintained and allowing more individuals to be immunised in a given time period.

NACI has outlined certain populations for which a specific products and/or doses may be preferred for a booster/additional dose, as outlined in Table 2.<sup>4</sup> See [NACI's guidance on booster COVID-19 vaccine doses](#) for additional rationale and considerations.

---

<sup>4</sup> However, if any of Pfizer (30 mcg), Moderna (50mcg) or Moderna (100mcg) are administered as a booster/additional dose, the dose should be considered valid and would not need to be repeated. See the MOH's COVID-19 [Vaccine Administration Errors and Deviations Guidance](#) for more details.

**Table 2: Rationale and Options for Vaccine Type and Dose offered for COVID-19 Vaccine Booster Doses in Certain Populations**

<b>Population</b>	<b>Vaccine type (and dose) for booster doses which may be preferred</b>	<b>Rationale or additional considerations</b>
<ul style="list-style-type: none"> <li>12 to 29 year olds (including those moderately to severely immunocompromised, and those with other underlying health condition(s) as mentioned above)</li> </ul>	<p>Pfizer-BioNTech (30 mcg).</p> <p>For individuals with severe immunosuppression, the vaccine offered may be based on clinical discretion.</p>	<p>Lower reported rates of myocarditis/pericarditis following vaccination with Pfizer-BioNTech (30 mcg) compared to Moderna (100 mcg) (based on second dose data).</p>

Population	Vaccine type (and dose) for booster doses which may be preferred	Rationale or additional considerations
<ul style="list-style-type: none"> <li>• ≥70 year olds</li> <li>• Residents of long-term care homes, retirement homes or seniors in other congregate settings</li> <li>• Moderately to severely immunocompromised individuals aged 30 years of age and older (for 3<sup>rd</sup> dose as part of the primary series and for the booster dose)<sup>5</sup></li> </ul>	<p>Either Moderna (100mcg) or Pfizer-BioNTech (30mcg) may be considered.</p> <p>Data suggest that Moderna COVID-19 vaccine may provide a more robust humoral and cellular immune response.</p> <p>If Moderna vaccine is being used as the booster product, a 100 mcg dose may be preferred, based on clinical discretion.</p>	<p>Moderna (100 mcg) induces somewhat higher antibody levels compared to Pfizer-BioNTech (30 mcg). Protection (against infection and severe disease) from a primary series with Moderna (100 mcg) may be more durable than Pfizer (30mcg). These populations may have less robust immune function (elderly) or a diminished immune response to the vaccine (some immunocompromised individuals). It is possible that Moderna (100 mcg) may induce a better immune response than Moderna (50 mcg).</p>
<ul style="list-style-type: none"> <li>• For all other populations in whom booster doses are recommended that have not been specified above.</li> </ul>	<p>Either Moderna (50 mcg) or Pfizer-BioNTech (30 mcg) are suitable products as a booster dose.</p>	<p>Authorized as booster doses by Health Canada</p>

---

<sup>5</sup> Moderately or severely immunocompromised adults receiving a booster dose after a primary series of three doses, are eligible to receive a total of four doses.

## Booster dose prioritized populations:

### 1. Residents of Long-Term Care Homes (LTCH), Retirement Homes (RH), Elder Care Lodges, and older adults living in other congregate settings

#### Rationale:

- The potential impact of the risk of transmission of the Delta and Omicron variants of concern in vulnerable older adult populations who live in high risk settings (i.e., congregate living with other vulnerable, high-risk adults) has been assessed, particularly in the context of emerging literature on the reduced immune response and the more rapid waning of antibody responses in this population. Some studies are showing decreases in protection against serious infection, and more notably in older adults ([NACI, 2021](#)). These individuals are at increased risk for severe disease because of their age and underlying medical conditions and are at a higher risk of exposure due to their daily interactions with staff and residents in a congregate living environment ([NACI, 2021](#)).
- Older Ontarians residing in congregate living settings were prioritized for the COVID-19 vaccine when the vaccines were first authorized; therefore, many completed their COVID-19 vaccination series early in the vaccine roll-out, leaving more time for waning should it occur. As well, many received their vaccines using the manufacturers' recommended interval. Evidence to date suggests that, compared to longer intervals, shorter intervals between first and second doses result in lower immune responses and therefore may also result in more rapid waning of protection, including against variants of concern ([NACI, 2021](#)).
- Vaccines have been effective against COVID-19 in Long Term Care Homes in the 3-4 months after vaccination, but outbreaks are still occurring. In these outbreaks, fully vaccinated residents are being infected, and in some instances leading to severe illness and death. Offering a booster/4th dose of COVID-19 vaccine to this population is intended to help increase protection and prevent outbreaks among this vulnerable population. See NACI's [Guidance on booster COVID-19 doses in Canada](#) for more information.
- Other congregate settings may include assisted-living facilities, chronic care hospitals, naturally occurring congregate retirement settings/congregate senior's apartment buildings, or older adults living in congregate settings for

people with developmental disabilities, mental health and addictions issues, etc.<sup>6</sup>

## 2. Adults ≥50 years of age

### Rationale:

- Older adults are more likely to experience severe illness, hospitalization, and death from COVID-19 infection, due to their age and underlying medical conditions. Among the fully vaccinated, older age groups (80 years of age and over with the highest, followed by those aged 70 to 79) have the highest hospitalization and mortality rates from COVID-19 compared to younger age groups who are fully vaccinated ([NACI, 2021](#)).
- There is evidence that demonstrates waning immunity and decreased vaccine effectiveness against infection over time after a primary COVID-19 vaccine series in the older adult population. Although protection against severe COVID-19 outcomes appears to be more durable over time than protection against asymptomatic or mildly asymptomatic infection, some studies are showing decreases in protection against serious infection, and more notably in older adults. See NACI's [guidance on booster COVID-19 vaccine doses in Canada](#) for more details.
- Older adults were prioritized for the COVID-19 vaccine when the vaccines were first authorized; therefore, many completed their COVID-19 vaccination series early in the vaccine roll-out, leaving more time for waning should it occur. As well, many received their vaccines using the manufacturers' recommended interval. Evidence to date suggests that, compared to longer intervals, shorter intervals between first and second doses result in lower immune responses and therefore, may also result in more rapid waning of protection, including against variants of concern ([NACI, 2021](#)).

## 3. Health Care Workers

### Rationale:

- Health care workers are at an increased risk of COVID-19 infection due to their ongoing interactions and potential exposures to patients that are or may be infected with COVID-19 and can pose increased risk of transmission to vulnerable populations they care for if infected.

---

<sup>6</sup> Public Health Units can use their discretion, in collaboration with partner Ministries as needed, to determine eligible congregate settings.

- Health care workers are essential for maintaining health system capacity to minimize serious illness and overall deaths in Ontario while minimizing societal disruption as a result of the COVID-19 pandemic.
- Health care workers were prioritized early in Ontario's COVID-19 immunization program, leaving more time for waning should it occur, and many received their second doses at the product monograph interval. Evidence to date suggests that shorter intervals between doses results in lower antibody titres which may wane to below protective levels over time. While individuals who received their second dose in the primary COVID-19 vaccine series at a shorter interval from the first dose were well protected in the short-term, they may have produced lower antibody levels, which may decrease over time compared with those who had a longer interval between doses ([NACI, 2021](#)).
- Optimizing the protection of healthcare workers can help to balance any disproportionate burden of those taking on additional risks to protect the public, thereby upholding the ethical principle of reciprocity ([NACI, 2021](#)).
- Health Care Workers include:
  - Any [regulated health professionals](#) and any staff member, contract worker, student/trainee, registered volunteer, or other designated essential caregiver currently working in-person in a health care organization, including workers that are not providing direct patient care and are frequently in the patient environment (i.e., cleaning staff, research staff, other administrative staff).
  - Workers providing healthcare service or direct patient service in a congregate, residential or community setting outside of a health care organization.
  - See Appendix B for specific examples of health care workers.

#### **4. First Nations, Inuit and Métis Adults**

##### **Rationale:**

- First Nations, Inuit and Métis populations have been disproportionately affected by COVID-19 in Canada and have experienced higher rates of COVID-19 infection due to a number of intersecting inequities and factors related to the social determinants of health. Immunization of individuals in this population has the potential to reduce or prevent the exacerbation of intersecting health and social inequities ([NACI, 2021](#)).

- Remote or isolated communities may not have ready access to sufficient health care infrastructure; therefore, their risk for severe outcomes, including death, and societal disruption is proportionally greater than in other communities ([NACI, 2021](#)).
- First Nations, Inuit and Métis populations were eligible to receive their first and second doses early in the vaccination roll out, leaving more time for waning to occur. This population was also eligible for the shortened product monograph interval and evidence to date suggests that, compared to longer intervals, shorter intervals between first and second doses result in lower immune responses and therefore may also result in more rapid waning of protection, including against variants of concern.
- As per [NACI](#), whether or not booster dose vaccine programs are needed in distinct Indigenous communities should be determined by Indigenous leaders and communities, and with the support of public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples.

## **5. Recipients of a Viral Vector Vaccine Primary Series that was completed with only viral vector vaccines (AstraZeneca/COVISHIELD or Janssen COVID-19 vaccine)**

### **Rationale:**

- Vaccine effectiveness against severe COVID-19 outcomes with all vaccine types (including viral vector) remains high, but it is currently unclear to what extent the duration of protection may vary by vaccine product.
- In general, vaccine effectiveness against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes has consistently been lower for individuals receiving viral vector vaccines compared to mRNA vaccines. Emerging data on effectiveness suggests that vaccine protection against infection and symptomatic disease decreases more quickly with viral vector vaccines in comparison to mRNA vaccines, whereas the difference is less pronounced for severe disease. These individuals may become susceptible to infection sooner than people who received a primary series that included at least one dose of an mRNA vaccine ([NACI, 2021](#)).
- While there is limited evidence on duration of protection following a mixed viral vector and mRNA COVID-19 vaccination schedule, to date data from two studies indicate that vaccine effectiveness for those who received a mixed

schedule of AstraZeneca/COVISHIELD followed by an mRNA vaccine is similar compared to those who received a complete series of mRNA vaccines ([NACI, 2021](#)).

## Appendix A: List of Immunosuppressive Medications in Alphabetical Order

#	E	L	R
5-Aminosalicylic Acid (ASA)/mesalamine	Enbrel	Leflunomide	Rapamune
6- mercaptopurine (6-MP)	Entyvio	<b>M</b>	Rasuvo
<b>A</b>	Envarsus	Mayzent	Remicade
Abatacept	Erelzi	Methotrexate	Remsima
Actemra	etanercept	Metoject	Renflexis
adalimumab	<b>F</b>	mycophenolate	Rheumatrex
Advagraf	fingolimod	mofetil	Riabni
Amgevita	<b>G</b>	mycophenolic acid	Rinvoq
anakinra	Gengraf	Myfortic	risankizumab
apremilast	Gilenya	<b>N</b>	Rituxan
Arava	golimumab	Neoral	Rituximab
Avsola	guselkumab	<b>O</b>	Riximyo
azathioprine	<b>H</b>	Ocrelizumab	Ruxience
Azulfidine	Hadlima	Ocrevus	<b>S</b>
<b>B</b>	Hulio	ofatumumab	Salazopyrin
baricitinib	Humira	Olumiant	Sandimmune
belimumab	Hyrimoz	Orencia	Sarilumab
Benlysta	<b>I</b>	Otezla	Secukinumab
Brenzys	Idacio	Otrexup	Siliq
Brodalumab	Ilaris	ozanimod	Simponi
<b>C</b>	Imuran	<b>P</b>	Siponimod
canakinumab	Inflectra	Pentasa	sirolimus
Cellcept	infliximab	Prednisone*	Skyrizi
certolizumab	ixekizumab	(>20mg/day for 14 or more consecutive days)	Stelara
Cimzia	<b>K</b>	Procytox	sulfasalazine
Cosentyx	Kesimpta	Prograf	<b>T</b>
cyclophosphamide	Kevzara	Purinethol	tacrolimus
cyclosporine	Kineret		Taltz
			tocilizumab
			tofacitinib
			Tremfya
			Trexall

Truxima	ustekinumab	<b>X</b>	<b>Z</b>
<b>U</b>	<b>V</b>	Xeljanz	Zeposia
upadacitinib	vedolizumab		

\*or equivalent steroid dose (prednisone 20 mg = prednisolone 20 mg = methylprednisolone 16 mg = hydrocortisone 80 mg = dexamethasone 3 mg)

## Appendix B: List of Health Care Workers Eligible for Booster Doses

[Regulated health professionals](#) and any staff member, contract worker, student/trainee, registered volunteer, or other designated essential caregivers currently working in-person in a health care organization, including workers that are not providing direct patient care and are frequently in the patient environment (i.e., cleaning staff, research staff, other administrative staff) are included in the below:

- **All hospital and acute care staff including:**
  - Critical Care Units, Emergency Departments and Urgent Care Departments, COVID-19 Medical Units, Code Blue Teams, rapid response teams
  - General internal medicine and other specialists, Surgical care, Obstetrics
- **All patient-facing health care workers/staff involved in the COVID-19 response:**
  - COVID-19 Specimen Collection Centers, COVID-19 Isolation Centers
  - Mobile Testing Teams, COVID-19 Laboratory Services, Teams supporting outbreak response (e.g., IPAC teams supporting outbreak management, inspectors in the patient environment)
  - COVID-19 vaccine clinics and mobile immunization teams
  - Current members of Ontario's Emergency Medical Assistance Team (EMAT)
- **Medical First Responders** (ORNGE, paramedics, firefighters providing medical first response, police and special constables providing medical first response as part of their regular duties)
- **Health care workers and designated essential caregivers in congregate settings** (assisted living, correctional settings, shelters, LTCHs/RHs, supportive housing, hospices and palliative care settings, etc.)

- **Home and community health care workers, providing in-person care, including:**
  - Needle exchange/syringe programs & supervised consumption and treatment services
  - Indigenous health care service providers including but not limited to: Aboriginal Health Access Centers, Indigenous Community Health Centers, Indigenous Inter-professional Primary Care Teams, and Indigenous Nurse Practitioner-Led Clinics
  - Community health centres, chronic homecare, birth centres, dentistry and dental hygiene, Pharmacies, Primary care, Walk-in clinics, gynecology/obstetrics, Midwifery, Nurse practitioner-led clinics/Contract nursing agencies, Otolaryngology (ENT), medical and surgical specialities, medical transport, laboratory services, independent health facilities, health care providers in developmental services, mental health and addictions services
  - Health care workers in schools/daycare/campus, sexual health clinics, community diagnostic imaging, dietary/nutrition, audiology, naturopathy, holistic care, chiropractic, chronic pain clinics, kinesiology/physiotherapy, occupational therapy, psychiatry, acupuncture, registered massage therapy, psychotherapy, social work, public health